Icandra (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride decreases the liver’s production of glucose and improves the body’s sensitivity to insulin. Vildagliptin blocks the enzyme DPP‑4, which raises levels of natural incretin hormones, thereby increasing insulin release after meals and reducing glucagon secretion.

The specific dose of Icandra is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Icandra in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Icandra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Icandra combines a biguanide (metformin) with a DPP‑4 inhibitor (vildagliptin), offering dual action that many single‑agent therapies lack. Compared with metformin alone, it provides additional post‑prandial glucose control, and versus DPP‑4 inhibitor monotherapy, it adds the insulin‑sensitising benefits of metformin.

Icandra should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain product stability.

Icandra is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, especially in patients with renal or hepatic impairment, and severe hypoglycaemia when used with insulin or sulfonylureas. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or unexplained weakness occur.

Icandra is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, and in those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.